Developing revolutionary new drugs from monoclonal antibodies that target GPCRs

Find out how Dr. Kiyoshi Takayama, President of NB Health Laboratory, is using the Intellicyt iQue3 to develop revolutionary new drugs from mAbs that target G-protein coupled receptors (GPCRs).